These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Pea F; Viale P; Pavan F; Furlanut M Clin Pharmacokinet; 2007; 46(12):997-1038. PubMed ID: 18027987 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of teicoplanin. Wilson AP Clin Pharmacokinet; 2000 Sep; 39(3):167-83. PubMed ID: 11020133 [TBL] [Abstract][Full Text] [Related]
5. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Bellmann R; Falkensammer G; Seger C; Weiler S; Kountchev J; Joannidis M Int J Clin Pharmacol Ther; 2010 Apr; 48(4):243-9. PubMed ID: 20353745 [TBL] [Abstract][Full Text] [Related]
6. [Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics]. Choufane S; Lobjoie E; Tinturier F Ann Fr Anesth Reanim; 1996; 15(8):1168-72. PubMed ID: 9636789 [TBL] [Abstract][Full Text] [Related]
7. Influence of arterio-venous haemofiltration on teicoplanin elimination. Hillaire-Buys D; Peyriere H; Lobjoie E; Bres J; Ossart M; Despaux E Br J Clin Pharmacol; 1995 Jul; 40(1):95-7. PubMed ID: 8527277 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Yagasaki K; Gando S; Matsuda N; Kameue T; Ishitani T; Hirano T; Iseki K Intensive Care Med; 2003 Nov; 29(11):2094-5. PubMed ID: 14504724 [No Abstract] [Full Text] [Related]
9. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Pea F; Brollo L; Lugano M; Dal Pos L; Furlanut M Ther Drug Monit; 2001 Oct; 23(5):587-8. PubMed ID: 11591906 [No Abstract] [Full Text] [Related]
10. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Meyer B; Traunmüller F; Hamwi A; Hollenstein UM; Locker GJ; Sperr WR; Staudinger T; Thalhammer-Scherrer R; Burgmann H; Thalhammer F Int J Clin Pharmacol Ther; 2004 Oct; 42(10):556-60. PubMed ID: 15516025 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics during continuous haemofiltration. Bressolle F; Kinowski JM; de la Coussaye JE; Wynn N; Eledjam JJ; Galtier M Clin Pharmacokinet; 1994 Jun; 26(6):457-71. PubMed ID: 8070219 [TBL] [Abstract][Full Text] [Related]